Aarti Pharmalabs Faces Rs 59.50 Crore Stamp Duty Demand Regarding Demerger
Aarti Pharmalabs Ltd 路 Others (Uncategorized) 路 03 Sept 2026, 1:59 am
Aarti Pharmalabs Faces Rs 59.50 Crore Stamp Duty Demand Regarding Demerger Aarti Pharmalabs received an order on 1st Sep'26 from Gujarat stamp authorities levying Rs 59.50 crore in stamp duty and penalties. The 29th Aug'26 order alleges a short payment of stamp duty concerning the 21st Sep'22 NCLT-approved demerger of Aarti Industries' pharma division into Aarti Pharmalabs. The total liability includes Rs 25 crore in base stamp duty and Rs 34.50 crore in associated penalties. Management believes it has strong merits to contest the claims and will initiate appropriate legal actions to challenge the order.
Original exchange filing (PDF)
More announcements from Aarti Pharmalabs Ltd
- Intimation of sad demise of Promoter and Chairman Emeritus of the Company 路 16 Nov 2026
- Q2 FY 27 Earnings Call Transcript 路 04 Nov 2026
- Audio Recording of Conference Call for Investor and Analysts 路 30 Oct 2026
- Q2 FY 2027 Investor Presentation 路 29 Oct 2026
- Please find enclosed 路 29 Oct 2026
- Please find enclosed 路 29 Oct 2026
- Please find enclosed 路 29 Oct 2026
- Aarti Pharmalabs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 29 Oct 2026
